Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents
- 1 June 2016
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 102, 89-100
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling InhibitorsHypertension, 2010
- DORADO: Opportunity PostponedHypertension, 2010
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 LevelsHypertension, 2010
- Treatment of bevacizumab-induced hypertension by amlodipineInvestigational New Drugs, 2010
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of TreatmentClinical Cancer Research, 2009
- Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitorsAnnals of Oncology, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Calcium-Antagonist DrugsNew England Journal of Medicine, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986